Drawing for LKV

USPTO serial 79333344

LKV

Reviewed by CopyMark Law Group

Reg. 7045419Status 700Registered
Filing date
Status date
Registration date
May 9, 2023
Examiner
PETTICAN, NATHANIEL VINCIENT
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LKV?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James C. Watson

James C. Watson TraskBritt, P.C.230 South 500 East, #300Salt Lake City, UT 84102UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers; vaccines; chemical preparations in the nature of pharmaceutical preparations for pharmaceutical use, namely, for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancersACTIVE—
042Pharmaceutical research and development; pharmaceutical research and development in the nature of research, development, engineering and testing in the fields of pharmaceutical products, medicines and vaccines; pharmaceutical research and development in the nature of testing, inspection, research and development of pharmaceutical preparations, medicines and vaccines; pharmaceutical research and development in the nature of research and development services for vaccines and medicines; scientific research and development in the field of biotechnologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 27, 2024CHLDCHANGE OF OWNER RECEIVED FROM IB—
Sep 4, 2023FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 14, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 14, 2023FIMPFINAL DISPOSITION PROCESSED—
Aug 9, 2023FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 9, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 9, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Feb 21, 2023GPNXNOTIFICATION PROCESSED BY IB—
Feb 21, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 1, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 1, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 13, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 12, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 12, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 12, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2022RFNPREFUSAL PROCESSED BY IB—
Jul 13, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 12, 2022RFRRREFUSAL PROCESSED BY MPU—
Jun 22, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 21, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 21, 2022DOCKASSIGNED TO EXAMINER—
Feb 19, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 15, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 10, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance